Compare Alibaba Group (BABA) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Charles River Laboratories Intl. Inc — how do they compare? Alibaba Group trades at $118.68 (market cap $270.95B), while Charles River Laboratories Intl. Inc trades at $228.24 (market cap $11.14B). The key difference: Alibaba Group is far larger — about 24.3× Charles River Laboratories Intl. Inc's market cap, and Alibaba Group pays a 0.93% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BABA | CRL | |
|---|---|---|
Market Cap | $270.95B | $11.14B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $233.60 |
52-Week Low | $94.83 | $145.57 |
Enterprise Value | $265.77B | $14.00B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $112.35, up 0.02% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with robust fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 17.36 appear reasonable. The stock faces headwinds from securities investigations but benefits from AI-driven optimism in cloud growth.
Outlook remains positive given Wall Street's $195 price target and 86% buy ratings, though risks include legal overhangs and earnings volatility. AI and cloud initiatives offer growth catalysts, but investors should monitor regulatory developments and quarterly execution against expectations.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
